A rational approach to management of alendronate-related subtrochanteric fractures

Journal of Bone and Joint Surgery - Series B

Volumn 92, Issue 5, 2010, Pages 679-686

  De Das, S ^a,a   Setiobudi, T ^a   Shen, L ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE RADIOGRAPHY; BONE TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE FIXATION; FRACTURE HEALING; FRACTURE NONUNION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MALE; MEDICAL RECORD REVIEW; OSTEOPOROSIS; OSTEOSCLEROSIS; PAIN; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; FEMORAL FRACTURES; FEMUR; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURES, STRESS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 77951838971     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.92B5.22941     Document Type: Article

References (27)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541
2. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199
3. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938
4. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301
5. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg [Br] 2007;89-B:349-353 (Pubitemid 46563912)
6. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-231
7. Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006;355:2048-2050 (Pubitemid 44708036)
8. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-350 (Pubitemid 351630250)
9. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in post-menopausal women taking alendronate. N Engl J Med 2008;358:1304-1306
10. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007;13:485-489
11. Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007;25:333-336 (Pubitemid 47283272)
12. Sims SH. Subtrochanteric femur fractures. Orthop Clin North Am 2002;33:113-126
13. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-620 (Pubitemid 30174014)
14. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004;19:999-1005.
15. Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebrae. J Bone Miner Res 2003;18:512-520
16. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002;17:2237-2246
17. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69:281-286
18. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009;20:887-894
19. Seigmund T, Allen MR, Burr DB. Failure of mineralized collagen fibrils: modeling the role of collagen cross-linking. J Biomech 2008;41:1427-35 (Erratum in: J Biomech 2009;42:404).
20. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759
21. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999;101:18-26.
22. Stock JL, Bell NH, Chesnut CH 3rd, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-297
23. McKenna MJ, Kleerekoper M, Ellis BI, et al. Atypical insufficiency fractures confused with Looser zones of osteomalacia. Bone 1987;8:71-78
24. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009;24:1998-2006.
25. Jobke B, Pfeifer M, Minne HW. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res 2009;50:46-54.
26. No authors listed. FRAX: WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX. (date last accessed 18 March 2010).
27. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg [Am] 2009;91-A:2556-2561